Analysis of N-Nitrosodimethylamine (NDMA) & N-Nitrosodiethylamine (NDEA) in pharmaceutical substance by HSGCMS

Applications | 2018 | ShimadzuInstrumentation
GC/MSD, HeadSpace, GC/SQ
Industries
Pharma & Biopharma
Manufacturer
Shimadzu

Significance of the Topic


N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) are classified as probable human carcinogens and can enter pharmaceutical products as process-related impurities or environmental contaminants. Their low regulatory limits and high toxicity necessitate robust analytical methods to ensure drug safety and compliance.

Objectives and Study Overview


This study aimed to develop and validate a headspace gas chromatography–mass spectrometry (HS-GCMS) method based on USFDA Office of Testing and Research guidelines for the trace-level quantitation of NDMA and NDEA in active pharmaceutical ingredients (APIs) such as Valsartan, Losartan, and Olmesartan‐Medoxomil.

Methodology and Instrumentation


  • Instrument: Shimadzu GCMS–QP2020 NX coupled with HS‐20 headspace autosampler.
  • Column: Shimadzu Stabilwax capillary (30 m × 0.32 mm ID, 0.25 µm film thickness).
  • Headspace conditions: 120 °C oven, 125 °C sample line, 130 °C transfer line, 1 mL loop, 103 kPa fill pressure, 15 min equilibration.
  • GC conditions: splitless injection, helium carrier at 1.60 mL/min, temperature program from 40 °C to 230 °C.
  • MS settings: electron ionization at 70 eV, SIM acquisition monitoring m/z 74, 42, 43 for NDMA and m/z 102, 57, 56, 44 for NDEA.
  • Calibration: external standards at 2.5, 5.0, 7.5, and 10 µg/L in DMSO.

Main Results and Discussion


The method exhibited excellent linearity (r2 > 0.999) over 2.5–10 µg/L. Limits of quantitation at 2.5 µg/L showed signal‐to‐noise ratios > 100. Precision studies yielded relative standard deviations below 5% for NDMA and 8% for NDEA. Spike‐recovery experiments in Valsartan, Losartan and Olmesartan‐Medoxomil APIs demonstrated recoveries between 88% and 115%, confirming method accuracy and reliability.

Benefits and Practical Applications


  • High sensitivity and specificity for trace nitrosamine detection.
  • Rapid analysis through ultrafast scanning and Shimadzu’s ASSP™ functionality.
  • Reproducible results supporting regulatory compliance in pharmaceutical QA/QC.

Future Trends and Potential Applications


Advancements in headspace automation and high‐throughput GCMS workflows will further enhance screening capacity. Expanding the methodology to other nitrosamine analogues and complex matrices will address emerging safety concerns across pharmaceutical and environmental testing.

Conclusion


The validated HS‐GCMS method on the Shimadzu GCMS‐QP2020 NX delivers a robust, sensitive, and reproducible approach for quantifying NDMA and NDEA in APIs, ensuring compliance with stringent regulatory standards and safeguarding public health.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Analysis of N-Nitrosodimethylamine (NDMA) & N-Nitrosodiethylamine (NDEA) in pharmaceutical substance by HSGCMS/MS
Quantitation of NDMA and NDEA in Metformin and 5 Sartan APIs as per the EDQM method Procedure B
Quantitation of 7 Nitrosaminesin API by HSGC-MS/MS as per proposed USP General Chapter <1469>
Quantitation of 6 N-Nitrosamines in Metformin and 5 Sartan APIs as per the EDQM method Procedure C